Express Pharma

Suven Life Sciences gets product patents from Israel, Japan


These patents are valid through 2036 and 2034 respectively

Suven Life Sciences has been granted a product patent each by Israel and Japan, for a new chemical entity (NCE) that is used in the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2036 and 2034 respectively, the company said in a BSE filing.

“We are by the grant of these patents to Suven for our pipeline of molecules in the Central nervous system (CNS) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Venkat Jasti, CEO, Suven Life Sciences said. The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s and schizophrenia, it added.



Comments are closed.